What Is Simponi, and Why Does It Matter? The FDA has approved Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kilograms (33 pounds).
NEW YORK, Oct 17 (Reuters) - Johnson & Johnson's new rheumatoid arthritis drug, Simponi, when used in combination with the common treatment methotrexate was significantly more effective at inhibiting ...
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of Alvotech’s ...
GUANGZHOU, China, July 16, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today ...
NEW YORK, April 13 (Reuters) - Johnson & Johnson and Schering-Plough Corp said on Monday that Canadian regulators had approved use of their experimental once-monthly drug Simponi to treat moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results